Objective: We evaluated the incidence of cardiovascular disease (CVD) in individuals whose blood pressure (BP) management strategy would change with adoption of recent US hypertension guidelines in two large, community-based cohorts with different racial and geographic compositions: the Framingham and Jackson Heart Studies (FHS and JHS).
chronic kidney disease (CKD). The guideline committee determined that there was insufficient evidence to support the previous, more aggressive, treatment thresholds [1] . Hypertension guidelines have great potential impact on population health and have been suggested to be partly responsible for improvements in SBP in the United States over the past 20 years [3] . If fully implemented, the JNC 8 guidelines are predicted to affect the treatment recommendations of up to 20 million Americans [4] , and as a result, the guidelines have been the subject of considerable debate [5, 6] .
To further understand the impact of recent changes to the BP treatment guidelines, we compared the 'real-world' incidence of cardiovascular disease (CVD) among individuals whose BP management matched the less aggressive targets advocated by JNC 8, with those whose management was consistent with JNC 7 recommendations. We hypothesized that less aggressive BP treatment would be associated with a higher risk of CVD regardless of age group. We tested this hypothesis in two large, community-based cohorts with different racial and geographic backgrounds: the predominantly white Framingham Heart Study (FHS) and the allblack Jackson Heart Study (JHS).
METHODS

Study sample
The design and enrollment of the JHS cohort and FHS Offspring cohort have been described previously [7] [8] [9] . Of the 5301 JHS participants who attended the baseline examination (performed in [2000] [2001] [2002] [2003] [2004] , we excluded those with missing BP measurements or antihypertensive treatment status (n ¼ 990), prevalent CVD (n ¼ 959), prevalent CKD (CKD, defined as creatinine >2 mg/dl; n ¼ 11), missing covariates (n ¼ 376), or follow-up time less than 1 year (n ¼ 17), yielding a sample of 2948 individuals.
In the FHS, participants attending the first (1971) (1972) (1973) (1974) (1975) , third (1983) (1984) (1985) (1986) (1987) , or sixth (1995-1998) Offspring examination cycles were eligible for inclusion. From 12 529 participant-visits, we excluded those with missing BP measurements or unknown hypertension treatment status (n ¼ 56), prevalent CVD (n ¼ 746), CKD (n ¼ 19), no follow-up (n ¼ 47), and missing covariates (n ¼ 424). These resulted in a final sample of 11 237 individual observations (4715, 3467, and 3055 from examination cycle one, three, and six). All participants in both cohorts provided written informed consent, and the study protocols were approved by each study's institutional review board.
Classification of blood pressure categories
In both studies, seated BP measurements were obtained using a mercury column sphygmomanometer and the average of two measurements obtained using a standardized protocol was recorded. In the JHS, hypertension treatment status was determined by medication review or self-report. In the FHS, hypertension treatment status was ascertained by a questionnaire. Each participant was assigned to one of five mutually exclusive BP categories based on their BP reading and their hypertension treatment status (Supplemental Table 1 , http://links.lww.com/HJH/A853). Category 1 ('no hypertension by JNC 7 or JNC 8') included untreated participants with SBP less than 140 mmHg and DBP less than 90 mmHg. Category 2 ('need BP medications by JNC 7, no medications by JNC 8') consisted of untreated participants with SBP 140-149 mmHg and DBP less than 90 mmHg. Category 3 ('successfully treated by JNC 7, unnecessarily treated by JNC 8') included participants with treated SBP less than 140 mmHg and DBP less than 90 mmHg. Category 4 ('inadequately treated by JNC 7, successfully treated by JNC 8') contained participants with treated SBP 140-149 mmHg and DBP less than 90 mmHg. Category 5 ('hypertension by JNC 7 and JNC 8') consisted of all other participants (SBP ! 150 mmHg and/or DBP ! 90 mmHg regardless of hypertension treatment status).
Outcome ascertainment
The outcome was a first CVD event, defined as a composite of fatal and nonfatal myocardial infarction, coronary insufficiency, angina, stroke or transient ischemic attack, intermittent claudication, or heart failure [10] . FHS participants are under continuous surveillance for the occurrence of CVD events, which are adjudicated by a committee of three experienced physicians after a detailed review of all pertinent medical records, examination visits, and health history updates. Events in JHS were ascertained by a combination of active and passive surveillance through annual health updates and review of discharge lists and death certificates from local hospitals [11] .
Covariates
A cardiovascular-focused physical examination, anthropometry, and phlebotomy (for assessment of CVD risk factors) were performed at each examination cycle of the FHS and at the baseline visit of the JHS. Participants were defined as having diabetes if they had nonfasting blood glucose at least 200 mg/dl, fasting blood glucose of at least 126 mg/dl, had hemoglobin A1c concentrations at least 6.5% (for JHS only), or were taking medication for diabetes [12] . Smoking history was self-reported, and we defined current smoking as regular cigarette smoking within the prior year.
Statistical analysis
The assigned BP category was the exposure of interest for all analyses, and follow-up was censored at 12 years after each examination. By using pooled repeated observations [13] , FHS participants were eligible to reenter the analyses if they did not have a prevalent CVD event in the follow-up window. We calculated incidence rates of CVD for each cohort overall, and stratified by age group (<60 years, !60 years). Kaplan-Meier plots were produced for each cohort, not accounting for competing risk of non-CVD mortality. To evaluate the associations of each BP category with incident CVD, we used Cox proportional hazards regression models treating category one ('no hypertension by JNC 7 or JNC 8') as referent. The assumption of proportionality of hazards was tested by assessing the interaction between time to CVD (log-transformed) and BP category, which held for the FHS and for the JHS (after excluding individuals with <1 year of follow-up), P more than 0.05 for both cohorts. We stratified by baseline examination and used robust sandwich covariance estimators to account for correlated observations within participants (in FHS only). In multivariable models, we adjusted for age at least 60 years (yes/no), sex, the ratio of total to HDL cholesterol, diabetes (yes/no), and current smoking. In secondary analyses, we adjusted for age as a continuous variable. Effect modification by age group, sex, and diabetes status was tested using multiplicative interaction terms. We then retested associations within subgroups of statistically significant effect modifiers.
We performed all analyses separately in FHS and JHS, and then we conducted a meta-analysis to combine results. We used fixed effect models for the meta-analyses to avoid excess leverage from the smaller sample (JHS). As a sensitivity analysis, a random-effects meta-analysis was performed.
To account for four different comparisons with the referent group, a Bonferroni correction was used to adjust our P values (calculated P values were multiplied by four) and confidence intervals (CIs). Therefore, a two-sided adjusted P value of less than 0.05 (after Bonferroni correction) was used to assess statistical significance for all analyses. All analyses were performed with SAS version 9.3 (Cary, North Carolina, USA).
RESULTS
Characteristics of the study samples are displayed for each cohort (Table 1) . Overall, individuals included in this investigation were middle-aged to older, and over half were women. There are several notable differences in baseline characteristics between the FHS and JHS samples, likely representing both demographic differences in the two cohorts and secular trends in cardiovascular risk factors (the baseline JHS examination occurred subsequent to all FHS examination cycles included in this investigation). JHS participants had higher mean BMI and were more likely to be women, to have diabetes, and to be receiving medications for treatment of high BP, whereas smoking was more common in FHS participants. The proportion of participants placed into each of the BP categories also varied substantially between the two cohorts with JHS participants less likely to be free of hypertension (category 1), but substantially more likely to have treated BP of less than 140/less than 90 (category 3), likely reflecting observations made in different time periods as noted above.
Incidence of cardiovascular disease by blood pressure category CVD events were observed in 1047 of 11 237 individuals (9.3%) in the FHS, and 230 of 2948 participants (7.8%) in the JHS, over mean follow-up times of 11.0 years (range 0-12 years) in FHS and 8.9 years (range 1.1-11.2 years) in JHS. We observed an increased incidence of CVD for each of the BP categories when compared with the referent group that was free of hypertension ( Fig. 1) .
Individuals in category 2 ('needs BP medications by JNC 7, no medications by JNC 8') had higher absolute incidence rate of CVD in both cohorts compared with those without hypertension ( Table 2) . Upon multivariable adjustment, these individuals had approximately 90% increased risk of CVD compared with the referent group among FHS participants and in the meta-analyzed results, whereas the risk in JHS was of borderline statistical significance (Fig. 2) .
Category 3 participants ('successfully treated by JNC 7, unnecessarily treated by JNC 8') displayed elevated risk of CVD, with a two-fold to three-fold higher risk than those with no hypertension in both the FHS and JHS in multivariable-adjusted models (Fig. 2) . The observed relations with CVD were also elevated for category five individuals ('hypertension by JNC 7 and JNC 8'), but were, overall, similar to other BP categories with a two-fold to 3.3-fold higher risk of CVD in multivariable-adjusted analyses (Fig. 2) .
Individuals in category 4 ('inadequately treated by JNC 7, successfully treated by JNC 8') had particularly high absolute incidence rate of CVD in the FHS, and the incidence was also elevated in the JHS (Table 2 ). These relations persisted in multivariable-adjusted Cox models, with a 2.7-3.5-fold higher risk of CVD in this group compared with the referent group in both cohorts (Fig. 2) . In secondary analyses, we evaluated the associations of BP category with incident CVD after including age as a continuous variable in the multivariable-adjusted model (Supplemental Fig. 1 , http://links.lww.com/HJH/A853), and the results were similar, although the hazard ratios were somewhat lower on average.
Evidence for modification of the effect of BP treatment group on incident CVD was observed for age group (P for interaction 0.0002) and diabetes status (P for interaction 0.009), but not for sex (P for interaction 0.23) in the FHS. In the JHS analyses, no effect modification by age group, diabetes status, or sex was observed (P for interaction >0.05 for all).
Effect of age group
We performed subgroup analyses stratified by age group. Due to low numbers of individuals in certain BP categories, the statistical power in each cohort was limited (Supplemental Table 2 , http://links.lww.com/HJH/A853). Among those aged less than 60 years, we observed similar results in the meta-analysis as we did in the overall analyses, with each BP category demonstrating a statistically significant increase in the hazards of CVD when compared with the referent group, and the highest individual risk was observed for category 4 ('inadequately treated by JNC 7, successfully treated by JNC 8') ( Table 3) . For those at least 60 years of age, the relative hazards for each BP category were lower due to an increased risk of CVD in the nonhypertensive group (category 1) ( Table 2 ). In the at least 60 years of age subgroup, no statistically significant increase in CVD risk was observed for individuals in category 2 ('needs BP meds by JNC 7, no meds by JNC 8'). Individuals in category 3 ('successfully treated by JNC 7, unnecessarily treated by JNC 8') displayed a 59% increased risk of CVD. 
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Effect of diabetes status
We then stratified by diabetes status, given the statistical evidence of effect modification in the FHS as noted above. The absolute incidence rates were substantially higher for those with diabetes versus those without (Supplemental Table 3 , http://links.lww.com/HJH/A853). Associations observed in individuals without diabetes were consistent with our overall results. However, the number of participants in each BP category with diabetes was low, and therefore our statistical power to detect statistically significant associations in those with diabetes was limited.
Sensitivity analyses
In our sensitivity analyses comparing the results from the fixed effect approach with the random effects approach within the meta-analysis, we found that although some of the I 2 statistics for the BP categories indicated a moderateto-high degree of heterogeneity between FHS and JHS, the hazard ratios and corresponding CIs from both approaches were identical to the second decimal digit.
We performed further sensitivity analyses in the Framingham sample by adjusting our multivariable models for additional clinical variables including pack years smoking (Supplemental Table 4 , http://links.lww.com/HJH/A853), lipid treatment, microalbuminuria, and left ventricular hypertrophy (Supplemental Table 5 , http://links.lww. com/HJH/A853) with only slight changes observed in the effect estimates for the relations between BP category and incident CVD (these additional variables were not available in a substantial proportion of the JHS sample, precluding extension of these sensitivity analyses to that cohort).
DISCUSSION
By using prospective data from two large community-based cohorts, we evaluated the incidence of CVD in individuals whose BP management strategy would change with the adoption of JNC 8 versus JNC 7 guidelines in whites and blacks. Absolute incidence rates were over two-fold higher for each BP category when compared with the nonhypertensive referent category, and particularly high absolute incidence rates were observed for the individuals with treated SBP 140-149 mmHg and DBP less than 90 mmHg, a group that is discordant between JNC 7 versus JNC 8 management strategies. These relations persisted in multivariable models adjusted for standard cardiovascular risk factors. In age-stratified analyses, individuals with treated SBP 140-149 mmHg and DBP less than 90 mmHg appeared to be at high risk in both the FHS analyses and the metaanalysis sample regardless of their age group (< versus !60 years).
Differences between cohorts
The present investigation was conducted in two community-based cohorts: the JHS consisting of black adults living in and around Jackson, Mississippi, and the FHS consisting of mostly white individuals of European descent predominantly residing in Massachusetts. However, a direct comparison between racial groups in this study is challenging because of several factors including secular changes in the distribution of risk factors and hypertension treatment between the two cohorts. We included participants from the FHS with baseline examinations in the 1970s, 1980s, and 1990s (to enhance our statistical power), whereas the JHS participants were enrolled beginning in 2000. Increasing awareness and treatment of hypertension over the course of the study period likely contributed to the higher prevalence of hypertension treatment in the JHS, and particularly to the number of participants who achieved on treatment SBP of less than 140 mmHg. Relatively high rates of hypertension treatment and of BP control in JHS compared with other predominantly black samples have been reported previously [14] . A healthy survivor bias might also exist when comparing JHS and FHS due to the higher mean age of the JHS sample included in the present investigation. Furthermore, current smoking was more prevalent in FHS participants, whereas the JHS sample had a higher proportion of women. These factors likely explain the lower absolute CVD incidence rates that we observed in the JHS sample in a contemporary time period when compared with the FHS sample in which observations used in the current study were accrued over a wider time-window from an earlier era. These data contrast with the most recent populationlevel data suggesting that blacks have similar rates of coronary heart disease but higher rates of stroke than non-Hispanic whites [15] . Nonetheless, the consistency of our results evaluating the association of the BP groups with CVD in both samples is striking, bearing in mind the effects of secular trends in BP treatment and in racial differences across the two racial groups.
Applicability of findings to recent US guideline changes
Our findings identify specific BP treatment categories that would be at increased risk assuming full implementation of the JNC 8 guidelines. Participants with treated SBP of 140-149 mmHg and DBP less than 90 mmHg (category 4) were at particularly high risk in the unadjusted and multivariableadjusted analyses, and these findings were consistent when restricted to those individuals 60 years of age or older. The JNC 8 guidelines recommend against further BP lowering in individuals in this category who are at least 60 years. Our findings suggest that this group is at considerable risk of developing CVD over the next 12 years if left untreated or uncontrolled to a level below 140 mmHg SBP. Future studies and guidelines should seek to define optimal treatment strategies to minimize CVD risk in this group.
The JNC 8 guidelines also recommend against initiating treatment for individuals with untreated SBP of 140-149 mmHg and DBP less than 90 mmHg (category 2) who are at least 60 years. We observed increased unadjusted incidence rates of CVD in these individuals in both cohorts, and in multivariable-adjusted models in the FHS and the meta-analysis samples. After stratifying by age at least 60 years, no statistically significant associations were Impact of changes to hypertension guidelines observed. However, the number of individuals in this subgroup was small and our statistical power to detect important associations may have been limited. Therefore, our results neither support nor question the JNC 8 recommendations for this group.
Although our findings indicate specific subgroups of hypertensive individuals who may be at particularly high risk of CVD if treated according to the less aggressive JNC 8 recommendations, our study was purely observational. Hence, inferring that these individuals would experience improved outcomes if a different treatment strategy were pursued is speculative and must be further investigated through clinical trials designed to test this premise. Numerous factors might contribute to differences in outcomes according to treated BP levels in our observational study. For example, individuals might be treated less or more aggressively as a consequence of other comorbidities, or by their physician's impression that they would be at increased risk from adverse effects with additional BP lowering. Moreover, pretreatment BP, antihypertensive medication class, and number of BP lowering agents used were not included in our analysis. Furthermore, secular trends in the awareness and treatment of hypertension (driven partly by changing BP treatment guidelines over time) also may partially affect our results. In addition, in observational studies, hypertension treatment may be a marker of both the chronicity and the severity of BP elevation. Our findings should, therefore, not be interpreted as supporting a more aggressive BP treatment strategy, but rather as demonstrating that groups of individuals remain at considerable residual risk of CVD if they are observed under conditions of a less aggressive (JNC 8) BP-lowering strategy.
Findings in the context of international guidelines
Although the present investigation focused on recent changes to US hypertension treatment guidelines, it is important to consider our findings within the context of other leading international guidelines. The most recent European Society of Hypertension/European Society of Cardiology Guidelines for the Management of Arterial Hypertension (last revised in 2013) [16] and National Institute for Health and Care Excellence (published in 2011) [17] both differ substantially from the JNC 8 guideline. Both consider BP treatment targets in the context of other cardiovascular risk factors and global CVD risk assessment. Furthermore, both of these guideline documents describe elderly individuals as being at least 80 years, and whereas treatment recommendations are less definite for this age group, targets of less than 140 mmHg/less than 90 mmHg are recommended for select patients. The recommendation for less aggressive treatment targets for individuals 60 years or older is unique to the JNC 8 guidelines. Our findings indicate that that these individuals are at particularly high risk for CVD if JNC 8 guidelines are followed.
Comparison with prior observational studies
Using registry-level data, Xu et al. [16] found SBP intensification thresholds more than 150 mmHg, but not more than 140 mmHg, to be associated with increased risk of CVD over a 10-year period. However, there are a number of differences between this study and the present investigation. In the study by Xu et al., all participants had been diagnosed with hypertension and were already treated with at least one antihypertensive medication, which was recently started or intensified. Furthermore, Xu et al. used the 'systolic intensification threshold' as the exposure variable, which was estimated from the lowest achieved SBP during the assessment period, whereas we categorized participants based on their baseline BP readings.
In a report from the Northern Manhattan Study, Dong et al. [17] demonstrated elevated risks of stroke in individuals with SBP 140-149 mmHg compared with those with an SBP less than 140 mmHg, consistent with our findings. In their sample, the increased risk was especially profound among Hispanics and non-Hispanic blacks. In the present investigation, we did not observe a higher risk among blacks, but several features of our study samples may explain this finding, as discussed above.
Methodological considerations
The present investigation was observational in design. Therefore, although we observed a particularly high risk of CVD in individuals with treated SBP of 140-149 mmHg, we cannot infer that this risk would be modified by more aggressive treatment. Unmeasured confounding and other factors that may affect decisions regarding BP targets in individual patients (detailed above) are likely to partially affect our findings. Despite the relatively large sample sizes, our statistical power was limited to detect differences in outcomes for certain subgroups, especially for those with diabetes. Furthermore, there were too few participants in our sample with CKD and we therefore excluded them from the analyses. Therefore, we cannot assess the outcomes in individuals with diabetes or CKD whose treatment recommendations were changed by JNC 8 guidelines. Lastly, we categorized individuals using resting BPs at the FHS clinic; other techniques such as ambulatory BP monitoring might more accurately reflect true hypertension burden [18] . Notwithstanding these limitations, our study has a number of important strengths, including long-term follow-up, comprehensive ascertainment of outcomes, and the ability to compare results from two large community-based cohorts with different racial and geographic characteristics.
In conclusion, in two well characterized communitybased samples with long-term follow-up, we observed higher absolute incidence and risk factor-adjusted hazards of CVD in white and black individuals whose treatment recommendations would change on the basis of adoption of the JNC 8 versus JNC 7 recommendations for the treatment of high BP. The risk was particularly high for individuals with treated SBP of 140-149 mmHg and DBP less than 90 mmHg, and was consistent in those 60 years of age or older, and in blacks and whites. Our findings demonstrate the absolute incidence and the relative hazards of CVD for individuals who may be potentially affected by recent changes to BP treatment guidelines, and we identify specific subgroups of hypertensive individuals that would be at substantial residual CVD risk when treated per the JNC 8 guidelines.
Reviewers' Summary Evaluations
Reviewer 1
The paper compares the level of blood pressure and the rate of CV disease in response to different guidelines in two different US populations. The advantage of the paper is the size of the population and the focus on the patients >60 years whose threshold and target BP are still matter of debate. The limitations are the heterogeneity of the sample size, the combination of the observations from two different studies, the impact of the observation that simply support a greater risk in patients with higher blood pressure. Moreover the comparison between the JNC-7 and JNC-8 is hard to support since the two guidelines where not the evolution of the same working group.
Reviewer 2
The present study suggests that less aggressive treatment of hypertension could be associated with substantial residual cardiovascular risk. This is important in the context of the JNC8 guidelines but less of an issue with European or Canadian guidelines where recent editions have, if anything, suggested tighter blood pressure control. This observational study is not without limitations. Importantly, cardiovascular risk factors accumulate over a long period of time, and modelling a hypothetical effect of changes in blood pressure targets in people who have been exposed to various antihypertensive treatments over decades cannot be perfectly precise. The fact that the authors were unable to test the impact of renal disease and diabetes limits its generalisability. Nevertheless, such analyses in cohorts with long-term follow up provide data that may not immediately change guidelines but certainly stimulate further research and specific prospective trials.
